Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice

• Published in: Nature medicine Vol. 29; no. 1; pp. 247 - 257
• Main Authors: Scheaffer, Suzanne M., Lee, Diana, Whitener, Bradley, Ying, Baoling, Wu, Kai, Liang, Chieh-Yu, Jani, Hardik, Martin, Philippa, Amato, Nicholas J., Avena, Laura E., Berrueta, Daniela Montes, Schmidt, Stephen D., O’Dell, Sijy, Nasir, Arshan, Chuang, Gwo-Yu, Stewart-Jones, Guillaume, Koup, Richard A., Doria-Rose, Nicole A., Carfi, Andrea, Elbashir, Sayda M., Thackray, Larissa B., Edwards, Darin K., Diamond, Michael S.
• Format: Journal Article
• Language: English
• Published: New York Nature Publishing Group US 01.01.2023; Nature Publishing Group
• Subjects: 2019-nCoV Vaccine mRNA-1273; 631/326/590/2293; 631/326/596/4130; Animals; Antibodies; Antibodies, Neutralizing; Antibodies, Viral; Antigens; Biomedical and Life Sciences; Biomedicine; Cancer Research; Coronaviruses; COVID-19; COVID-19 - prevention & control; COVID-19 Vaccines; Disease transmission; Effectiveness; Humans; Immune response; Immunization; Immunogenicity; Infectious Diseases; Metabolic Diseases; Mice; Molecular Medicine; mRNA; mRNA Vaccines; Neurosciences; Neutralization; Neutralizing; RNA, Messenger - genetics; SARS-CoV-2 - genetics; Severe acute respiratory syndrome coronavirus 2; Vaccine efficacy; Vaccines; Vaccines, Combined; Viral diseases

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants in the Omicron lineage has resulted in diminished Coronavirus Disease 2019 (COVID-19) vaccine efficacy and persistent transmission. In this study, we evaluated the immunogenicity and protective efficacy of two, re...